ECSP066752A - Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida - Google Patents

Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida

Info

Publication number
ECSP066752A
ECSP066752A EC2006006752A ECSP066752A ECSP066752A EC SP066752 A ECSP066752 A EC SP066752A EC 2006006752 A EC2006006752 A EC 2006006752A EC SP066752 A ECSP066752 A EC SP066752A EC SP066752 A ECSP066752 A EC SP066752A
Authority
EC
Ecuador
Prior art keywords
salt
methyl
phenyl
tartrate
ilmetile
Prior art date
Application number
EC2006006752A
Other languages
English (en)
Inventor
Paul William Manley
Michael Mutz
Hans Michael Buerger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066752(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066752A publication Critical patent/ECSP066752A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a las sales de adición de ácido de 4-[4-metil-1-piperazinilmetil]-N-[4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]fenil]-benzamida, que se seleccionan del grupo que consiste de una sal de tartrato, tal como una sal de (D)(-)tartrato o sal de (L)(+) tartrato, sal de clorhidrato, sal de citrato, sal de malato, sal de fumarato, sal de succinato, sal de benzoato, sal de bencensulfonato, sal de pamoato, sal de formiato, sal de malonato, sal de 1,5-naftalendisulfonato, sal de silicato, sal de ciclohexansulfamiato, sal de lactato, sal de mandelato, sal de glutarato acuosa, sal de adipato, sal de escuarato, sal de vanilato, sal de oxaloacetato, sal de ascorbato, y sal de sulfato.
EC2006006752A 2004-02-04 2006-08-03 Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida ECSP066752A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54181704P 2004-02-04 2004-02-04

Publications (1)

Publication Number Publication Date
ECSP066752A true ECSP066752A (es) 2006-11-16

Family

ID=34837520

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006752A ECSP066752A (es) 2004-02-04 2006-08-03 Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida

Country Status (22)

Country Link
US (3) US20080249104A1 (es)
EP (1) EP1713792B1 (es)
JP (1) JP4937760B2 (es)
KR (2) KR20060135735A (es)
CN (1) CN100558723C (es)
AR (1) AR047530A1 (es)
AU (1) AU2005211514B2 (es)
BR (1) BRPI0507464A (es)
CA (1) CA2553887C (es)
EC (1) ECSP066752A (es)
IL (1) IL177005A (es)
MA (1) MA28428B1 (es)
MY (1) MY144177A (es)
NO (1) NO20063942L (es)
NZ (1) NZ548714A (es)
PE (1) PE20051096A1 (es)
PH (1) PH12013500157A1 (es)
RU (1) RU2375355C2 (es)
TN (1) TNSN06243A1 (es)
TW (1) TWI347186B (es)
WO (1) WO2005075454A2 (es)
ZA (1) ZA200605972B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
UY29964A1 (es) 2005-11-25 2007-06-29 Novartis Ag Formas de cristal f,g,h,i, y k del mesilato de imatinib
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (en) * 2007-05-07 2008-11-13 Natco Pharma Limited A process for the preparation of highly pure imatinib base
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
EP2086520A1 (en) 2007-09-25 2009-08-12 Teva Pharmaceutical Industries Ltd. Imatinib compositions
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
EP2445502B2 (en) 2009-06-25 2022-09-28 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2775400A1 (en) 2009-09-28 2011-03-31 Medizinische Universitat Wien New use of pdgfrbeta inhibitors
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
KR101138840B1 (ko) * 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
KR20130055576A (ko) 2010-03-15 2013-05-28 낫코 파마 리미티드 고순도의 결정질 이마티닙 염기를 제조하는 방법
EA024088B1 (ru) 2010-06-18 2016-08-31 КРКА, д.д., НОВО МЕСТО α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
WO2013150052A1 (en) 2012-04-04 2013-10-10 Intervet International B.V. Soft chewable pharmaceutical products
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
CA3172586C (en) 2013-07-31 2025-10-14 Avalyn Pharma Inc. IMATINIB AEROSOL COMPOUNDS AND RELATED USES
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3691861B2 (ja) * 1994-09-14 2005-09-07 株式会社東芝 光ディスク用光パルス幅制御装置
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
ES2274234T3 (es) * 2002-03-15 2007-05-16 Novartis Ag 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3(4-piridin-3-il)pirimidin -2-ilamino)fenil)-benzamida para el tratamiento de enfermedades mediadas por ang ii.
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
UY29964A1 (es) * 2005-11-25 2007-06-29 Novartis Ag Formas de cristal f,g,h,i, y k del mesilato de imatinib

Also Published As

Publication number Publication date
TW200529854A (en) 2005-09-16
CN1914191A (zh) 2007-02-14
MY144177A (en) 2011-08-15
CA2553887A1 (en) 2005-08-18
PE20051096A1 (es) 2006-01-23
TNSN06243A1 (en) 2007-12-03
AU2005211514B2 (en) 2009-09-10
US20140051853A1 (en) 2014-02-20
US8513256B2 (en) 2013-08-20
KR20060135735A (ko) 2006-12-29
NZ548714A (en) 2009-08-28
AR047530A1 (es) 2006-01-25
CN100558723C (zh) 2009-11-11
CA2553887C (en) 2013-04-16
AU2005211514A1 (en) 2005-08-18
ZA200605972B (en) 2007-11-28
KR20120127525A (ko) 2012-11-21
IL177005A0 (en) 2006-12-10
IL177005A (en) 2014-05-28
JP2007520518A (ja) 2007-07-26
US20120142697A1 (en) 2012-06-07
MA28428B1 (fr) 2007-02-01
RU2375355C2 (ru) 2009-12-10
WO2005075454A3 (en) 2006-07-27
WO2005075454A2 (en) 2005-08-18
US20080249104A1 (en) 2008-10-09
JP4937760B2 (ja) 2012-05-23
BRPI0507464A (pt) 2007-07-10
NO20063942L (no) 2006-11-02
EP1713792B1 (en) 2014-04-30
RU2006131548A (ru) 2008-03-10
PH12013500157A1 (en) 2014-09-08
TWI347186B (en) 2011-08-21
EP1713792A2 (en) 2006-10-25

Similar Documents

Publication Publication Date Title
ECSP066752A (es) Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
UA84462C2 (ru) Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
ATE321556T1 (de) Behandlung gastrointestinaler stroma-tumoren
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
AR076433A1 (es) Sales inhibidoras de cdk
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
EA201270204A1 (ru) Таблетка
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
AR053984A1 (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
RU2016146560A (ru) Производные морфолин-пиридина
AR077692A1 (es) Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
TH74677A (th) รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด
DE602004022540D1 (de) Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes
NO20064114L (no) Fremgangsmate for fremstilling av N-arylpiperazinderivater
NZ602758A (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
NO20072501L (no) Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMS
DE602005018171D1 (de) Verfahren zur herstellung von ziprasidon
TH114424A (th) สารเตรียมชนิดของแข็ง
UY28498A1 (es) Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso.
ATE326970T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
CY1110806T1 (el) Μια κρυσταλλικη μεταβαλλομενου βαθμου ενυδατωσης ενυδρη μορφη toy (s)-6-(4-(2-((3-(9η-καρβαζολ-4-υλοξυ)-2-υδροξυπροπυλ]αμινο]-2-μεθυλπροπυλ) φαινοξυ)-3-πυριδινοκαρβοξαμιδιου ημιηλεκτρικο αλας
AR055284A1 (es) R-enantiomeros de n- propargil- 1- aminoindano, sales, composiciones y usos de los mismos